Safety Profile of the Fluoroquinolones

[1]  R. Mazzocchio,et al.  See Blockindiscussions, Blockinstats, Blockinand Blockinauthor Blockinprofiles Blockinfor Blockinthis Blockinpublication , 2022 .

[2]  Manfred Hauben,et al.  Defining ‘Signal’ and its Subtypes in Pharmacovigilance Based on a Systematic Review of Previous Definitions , 2009, Drug safety.

[3]  H. Leufkens,et al.  Pharmacovigilance of Biopharmaceuticals , 2009, Drug safety.

[4]  P. Tulkens,et al.  Terms and Conditions for Use of Pdf , 2022 .

[5]  L. Masserini.  L'uso dei farmaci in Italia , 2008 .

[6]  Arjun Srinivasan,et al.  Emergency department visits for antibiotic-associated adverse events. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[7]  Herman Goossens,et al.  European Surveillance of Antimicrobial Consumption (ESAC): quality indicators for outpatient antibiotic use in Europe , 2007, Quality & Safety in Health Care.

[8]  A. Mehlhorn,et al.  Infectious Diseases: Safety Concerns with Fluoroquinolones , 2007, The Annals of pharmacotherapy.

[9]  H. Goossens,et al.  Comparison of outpatient systemic antibacterial use in 2004 in the United States and 27 European countries. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[10]  H. Goossens,et al.  Antibiotic use in ambulatory care in Europe (ESAC data 1997–2002): trends, regional differences and seasonal fluctuations , 2007, Pharmacoepidemiology and drug safety.

[11]  John D Seeger,et al.  Incidence of Allergic Reactions Associated with Antibacterial Use in a Large, Managed Care Organisation , 2007, Drug safety.

[12]  Herman Goossens,et al.  European Surveillance of Antimicrobial Consumption (ESAC): outpatient quinolone use in Europe. , 2006, The Journal of antimicrobial chemotherapy.

[13]  E. Septimus,et al.  A Retrospective, Comparative Evaluation of Dysglycemias in Hospitalized Patients Receiving Gatifloxacin, Levofloxacin, Ciprofloxacin, or Ceftriaxone , 2005, Pharmacotherapy.

[14]  R. Owens,et al.  Antimicrobial safety: focus on fluoroquinolones. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[15]  P. Tulkens,et al.  Quinolones in 2005: an update. , 2005, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[16]  H. Goossens,et al.  Outpatient antibiotic use in Europe and association with resistance: a cross-national database study , 2005, The Lancet.

[17]  J. Travers,et al.  Moxifloxacin-associated drug hypersensitivity syndrome with toxic epidermal necrolysis and fulminant hepatic failure. , 2004, Archives of dermatology.

[18]  H. Goossens,et al.  European surveillance of antimicrobial consumption (ESAC): data collection performance and methodological approach. , 2004, British journal of clinical pharmacology.

[19]  E. V. van Puijenbroek,et al.  The Weber-curve pitfall: effects of a forced introduction on reporting rates and reported adverse reaction profiles , 2003, Pharmacy World and Science.

[20]  B. Stricker,et al.  Increased risk of achilles tendon rupture with quinolone antibacterial use, especially in elderly patients taking oral corticosteroids. , 2003, Archives of internal medicine.

[21]  G. Zhanel,et al.  Fluoroquinolone-associated tendinopathy: a critical review of the literature. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[22]  R. Leone,et al.  Adverse Drug Reactions Related to the Use of Fluoroquinolone Antimicrobials , 2003, Drug safety.

[23]  B. Stricker,et al.  Fluoroquinolones and risk of Achilles tendon disorders: case-control study , 2002, BMJ : British Medical Journal.

[24]  E. Brown,et al.  Effects of Coding Dictionary on Signal Generation , 2002, Drug safety.

[25]  R. Owens,et al.  Clinical use of the fluoroquinolones. , 2000, The Medical clinics of North America.

[26]  B. Stricker,et al.  Confounding by indication: an example of variation in the use of epidemiologic terminology. , 1999, American journal of epidemiology.

[27]  B. Bégaud,et al.  Is reporting rate a good predictor of risks associated with drugs? , 1999, British journal of clinical pharmacology.

[28]  S. Olsson,et al.  The Role of the WHO Programme on International Drug Monitoring in Coordinating Worldwide Drug Safety Efforts , 1998, Drug safety.

[29]  R. Owens,et al.  New generations of quinolones: with particular attention to levofloxacin. , 1997, Connecticut medicine.

[30]  F. Haramburu,et al.  Comparing the toxicity of two drugs in the framework of spontaneous reporting: a confidence interval approach. , 1996, Journal of clinical epidemiology.